In our cohort, CAM was detected in 60% of anti‐TIF‐1γ‐ and 20% of anti‐Mi‐2‐associated DM patients, which (i) basically reflects results from other larger patient series (43, 44) and (ii) emphasized the need for personalized risk‐stratified cancer follow‐up for both DM subgroups. This evidence concerns the gene TYRO3 and dermatomyositis.